VXRT

Vaxart Inc.

Last Updated:

Q2 '20

Price

quotes and stock data delayed 15 minutes

Cash

$44.4M

Burn Rate (Qtr)

$9.0M

Company Profile

Vaxart is focused on developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart’s oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Influenza Vaccine

Universal Influenza Vaccine

Phase 2

TBD

VXA-A1.1 (Oral Vaccine)

Seasonal Influenza / H1 influenza

Phase 3 (Initiation)

COVID-19 Oral Vaccine

COVID-19

Phase 1 Data

Q4 2020/Q1 2021

Recent Posts

See what the community is saying - click to see full post

VXRT - Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

Small Cap COVID-19 Vaccine Players

VXRT - FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon